LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.71
+0.00% today
Updated 2026-04-30
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.1M
Lyra Therapeutics Inc (LYRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.24M | $0.00 | $0.00 | $285000.00 | $1.36M | $1.56M | $1.53M |
| Revenue growth (YoY) | — | -100.0% | — | — | +378.2% | +14.3% | -1.5% |
| Cost of revenue | — | $27000.00 | $12.52M | $1.00M | $1.07M | $48.03M | $471000.00 |
| Gross profit | $1.24M | $-27000.00 | $-12.52M | $285000.00 | $1.36M | $1.56M | $1.53M |
| Gross margin | 100.0% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $4.97M | $12.03M | $12.52M | $29.69M | $38.80M | $48.03M | $43.77M |
| SG&A | $3.53M | $4.49M | $9.69M | $14.21M | $17.56M | $19.06M | $18.50M |
| Operating income | $-7.26M | $-16.52M | $-22.21M | $-43.62M | $-56.31M | $-67.12M | $-96.35M |
| Operating margin | -583.5% | — | — | -15303.5% | -4131.0% | -4308.1% | -6280.8% |
| EBITDA | $-7.18M | $-16.49M | $-22.11M | $-42.61M | $-53.92M | $-65.25M | $-60.26M |
| EBITDA margin | -576.9% | — | — | -14952.3% | -3956.2% | -4188.1% | -3928.4% |
| EBIT | $-7.26M | $-16.52M | $-22.21M | $-43.62M | $-54.99M | $-65.53M | $-60.73M |
| Interest expense | $1.23M | $213000.00 | $82000.00 | $102000.00 | $524000.00 | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.03M | $-16.31M | $-22.13M | $-42.41M | $-55.28M | $-62.68M | $-93.44M |
| Net income growth (YoY) | — | -170.5% | -35.7% | -91.7% | -30.3% | -13.4% | -49.1% |
| Profit margin | -484.6% | — | — | -14880.7% | -4055.6% | -4023.1% | -6090.9% |